Lactobacillus reuteri BNCC186563 Ameliorates Lipid Metabolism Disorder in Obese Mice by Activating the PPARα Signaling Pathway

Abstract

Obesity is a chronic disease that is now recognized as a global epidemic. Therefore, the need for effective therapeutic options to combat obesity cannot be overemphasized. Here, we demonstrate a novel protective role of Lactobacillus reuteri (L. reuteri) in obese mice. By using a mouse model of hyperlipidemia, we found that L. reuteri modulates lipid metabolism disorders in mice in a dose-dependent manner. Mechanistically, oral administration of L. reuteri alters mice's hepatic glycerophospholipid metabolic profile, thereby preventing lipid overaccumulation. In addition, L. reuteri activates hepatic PPARα signaling and promotes fatty acid oxidation for lipid lowering. To further confirm the critical role of the PPARα signaling pathway in obesity, we performed PPARα antagonist treatment experiments. The primary goal was to evaluate how L. reuteri intervention impacts the composition, functionality, and variety of liver metabolites in signaling pathways. The results showed that the PPARα antagonist GW6471 significantly reversed the weight loss effect of L. reuteri while altering the glycerophospholipid metabolic profile. Overall, L. reuteri ameliorates obesity in mice by modulating the PPARα pathway and glycerophospholipid metabolism, which may provide new ideas and avenues for promoting civic health.